SAN DIEGO , Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the underwriters' full exercise... Read More

SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are... Read More

SAN DIEGO , Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to... Read More

Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and 10-Meter Walk/Run Test (10mWRT) at approximately one year Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production,... Read More

SAN DIEGO , Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conferences: Cantor Global Healthcare Conference 2025 – New York, NY Wednesday, September 3, 2025 , at... Read More

Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned del-zota BLA submission at year end 2025 for DMD44 on track to be Avidity's first BLA submission On track for three potential BLA submissions over a 12-month period Strong balance sheet and cash runway to mid-2027 enabling global... Read More

Topline data readout from HARBOR study anticipated in Q2 2026 Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to potentially be the first globally approved drug for DM1 On track to share updates from ongoing MARINA-OLE™ trial of del-desiran including long-term 4 mg/kg efficacy and safety data in Q4 2025 SAN DIEGO , July 28, 2025 /PRNewswire/ --... Read More

On track for planned BLA submission for del-zota at year end 2025 SAN DIEGO , July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart zotadirsen... Read More

FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) Jeffrey M. Statland , M.D., Professor of Neurology, University of Kansas Medical Center , and FORTITUDE trial investigator, will present topline del-brax data from dose escalation cohorts in oral presentation Stephen Tapscott , M.D., Ph.D., Professor of Human Biology and Clinical... Read More

Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers Data support planned accelerated approval BLA submission in H2 2026 Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today,... Read More

Planning accelerated approval BLA submission in H2 2026, following topline data from FORTITUDE™ biomarker cohort in Q2 2026 Initiated global, confirmatory Phase 3 FORWARD™ study of del-brax 2mg/kg every six weeks Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new... Read More

SAN DIEGO , May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2025 , the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 71,000 shares of its common... Read More

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD Executing on global commercial infrastructure development and on track... Read More

SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025 , at 3:00... Read More

SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its... Read More

Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug... Read More

SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24 th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 , at 3:00 p.m.... Read More

Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswire/ -- Avidity Biosciences,... Read More

SAN DIEGO , March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 101,200 shares of its... Read More

On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts Plan to present functional data in fourth quarter of 2025 Investor and analyst webcast event today at 8:00 a.m. ET SAN DIEGO , March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to... Read More

Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025 , at 8:00 a.m. ET Key opinion leaders to participate in... Read More

SAN DIEGO , Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent... Read More

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD... Read More

SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 , at 3:10... Read More

SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its... Read More

SAN DIEGO , Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025 , the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 10,500 shares of its... Read More

SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common... Read More

Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025 On track to complete enrollment in del-desiran HARBOR TM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025 Eric Mosbrooker expands role to Chief Commercial Officer; Charles Calderaro III, Chief Technical Officer, and Kat... Read More

SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 720,400 shares of its... Read More

SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: 7th Annual Evercore ISI HealthCONx Conference on December 3 at 9:30 a.m. PT / 12:30 p.m. ET A live webcast of... Read More

SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 117,000 shares of its... Read More

Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2... Read More

Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event... Read More

Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18 , 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024 , at 8:00 a.m. ET SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA... Read More

Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers; del-brax 2 mg/kg will be administered every six weeks Enrollment in the del-brax biomarker cohort expected to be completed in 1H 2025; on track to initiate del-brax functional cohort in 1H 2025 In previously reported initial data, del-brax 2 mg/kg every six weeks showed... Read More

SAN DIEGO , Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 421,600 shares of its... Read More

SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root... Read More

SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: Chardan 8 th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET A live webcast... Read More

SAN DIEGO , Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 212,000 shares of its... Read More

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) SAN DIEGO ,... Read More

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET Cantor Global... Read More

SAN DIEGO , Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 52,100 shares of its common... Read More

SAN DIEGO , Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of... Read More

SAN DIEGO , Aug. 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the public of $41.00 per share. All of the shares to be sold in the offering are to... Read More

SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250 .0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to... Read More

Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA Breakthrough Therapy designation Avidity plans to accelerate initiation of... Read More

Delpacibart zotadirsen (AOC 1044) delivered unsurpassed muscle concentrations of PMO of 200 nM after three doses of 5 mg/kg Statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months Statistically significant increase of 25% of normal in dystrophin production and restored total dystrophin up to 54% of normal with delpacibart zotadirsen 5 mg/kg at four... Read More

SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 1, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 160,000 shares of its common... Read More

SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr. , J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive... Read More

SAN DIEGO , July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on July 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 128,200 shares of its common... Read More

SAN DIEGO , June 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on June 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 173,300 shares of its common... Read More

FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET SAN DIEGO , June 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is partnering with the FSHD Society and... Read More

SAN DIEGO , June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 12,132,500 shares of its common stock, including 1,582,500 shares sold pursuant to the underwriters' full exercise of... Read More

SAN DIEGO , June 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conference: TD Cowen Genetic Medicines & RNA Summit on June 20 at 8:20 a.m. PT/11:20 a.m. ET A live webcast of the event,... Read More

SAN DIEGO , June 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share. All of the shares to be sold in the offering are to be sold... Read More

SAN DIEGO , June 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant... Read More

Avidity plans to accelerate the initiation of registrational cohorts in FORTITUDE ™ trial Delpacibart braxlosiran (AOC 1020), the first investigational therapy to target the underlying cause of FSHD, provided greater than 50% mean reduction across multiple DUX4 regulated gene panels (2 mg/kg at four months) Trends of functional improvement including muscle strength, reachable workspace, and positive trends in patient and... Read More

Jeffrey M. Statland , M.D., Professor of Neurology, University of Kansas Medical Center , and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™ Avidity to host Volume 9 of investor and analyst event series via webcast June 12, 2024 , at 8:00 a.m. ET SAN DIEGO , May 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a... Read More

SAN DIEGO , May 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,500 shares of its common... Read More

SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec , M.Pharm, MBA to its board of directors. Ms. Skerjanec... Read More

Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ trial in 2H24 Presented positive long-term del-desiran data from MARINA-OLE™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vHOT as primary,... Read More

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: BofA Securities 2024 Health Care Conference on May 15 at 8:00 a.m. PT / 11:00 a.m. ET A live webcast of the... Read More

Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple functional measures in DM1 compared to END-DM1 natural history data SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called... Read More

SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common... Read More

SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT / 12:40 p.m. ET 23 rd... Read More

SAN DIEGO , March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common... Read More

Avidity accelerates global Phase 3 HARBOR™ study initiation to Q2 2024 following regulatory agreement on study design; primary endpoint is video hand opening time (vHOT) and secondary endpoints include muscle strength and activities of daily living Delpacibart etedesiran (AOC 1001) demonstrated consistent and durable improvements in myotonia, muscle strength and activities of daily living in people with DM1 in long-term data... Read More

SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day ® , highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on... Read More

Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents and investments expected to provide runway into late 2026 Avidity to host Volume 8 of investor and analyst event series via... Read More

Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024 Avidity to report data from clinical programs for people living with FSHD and DMD44 later this year SAN DIEGO , Feb. 28, 2024 /PRNewswire/ --... Read More

SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences: TD Cowen 44 th Annual Health Care Conference on March 5 at 10:30 a.m. PT / 1:30 p.m. ET Leerink Partners... Read More

SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,500 shares of its... Read More

SAN DIEGO , Feb. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to AOC 1044, the company's investigational therapy for the treatment of Duchenne muscular... Read More

John W. Day, MD, PhD, Professor of Neurology and Pediatrics, and Director, Division of Neuromuscular Medicine, Stanford University School of Medicine and a principal investigator in END-DM1, ongoing natural history study will join Avidity management to present data from MARINA-OLE™ Avidity to host Volume 8 of investor and analyst event series via webcast March 4, 2024 , at 8:00 a.m. ET SAN DIEGO , Feb. 15, 2024 /PRNewswire/... Read More

SAN DIEGO , Jan. 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20 , 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,650 shares of its... Read More

Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO , Jan. 5,... Read More

SAN DIEGO , Dec. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its... Read More

AOC 1044 delivered up to 50-times greater concentrations of PMO in skeletal muscle following a single dose compared to peptide conjugated PMOs in healthy volunteers AOC 1044 was well tolerated, demonstrated statistically significant exon 44 skipping compared to placebo of up to 1.5% in healthy volunteers after a single dose of 10 mg/kg and increased exon skipping in all participants Avidity plans to provide first look at AOC... Read More

Avidity to receive $100 million up front with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity's proprietary AOC platform technology SAN DIEGO , Nov. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a... Read More

SAN DIEGO , Nov. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 27,000 shares of its... Read More

SAN DIEGO , Nov. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conference: 6 th Annual Evercore ISI HealthCONx Conference on November 28 at 9:30 a.m. PT/12:30 p.m. ET A live webcast of... Read More

Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1 (DM1) AOC 1044 receives Orphan Designation for the treatment of DMD in US and EU Avidity remains on track to report data readouts from three clinical... Read More

SAN DIEGO , Oct. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,200 shares of its... Read More

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing improvements in myotonia, muscle strength and mobility New long-term safety data of AOC 1001 continue to demonstrate favorable safety and tolerability with over 200 infusions totaling 46.2 patient-years of exposure Data from 12... Read More

SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023 , in Charleston, South... Read More

SAN DIEGO , Sept. 25, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences: Chardan 7 th Annual Genetic Medicines Conference on October 3 at 6:00 a.m. PT/9:00 a.m. ET BMO Biopharma... Read More

SAN DIEGO , Sept. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2023 , the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,300 shares of its... Read More

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community leaders, patients, caregivers, and legislators in educational briefing to highlight the latest scientific advancements in myotonic dystrophy research and development Company advancing clinical development programs for three types of... Read More

SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, being held September 7-9, 2023 , in Washington, D.C. POSTER... Read More

SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences: 2023 Wells Fargo Healthcare Conference on September 6 at 5:45 a.m. PT / 8:45 a.m. ET 2023 Cantor Global... Read More

SAN DIEGO , Aug. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,100 shares of its common... Read More

SAN DIEGO , Aug. 15, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. ( Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1044, the company's investigational therapy in development for the treatment of Duchenne muscular... Read More

Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the second quarter... Read More

SAN DIEGO , July 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on July 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 33,150 shares of its common... Read More

SAN DIEGO , June 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on June 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 23,650 shares of its common... Read More

Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a preliminary assessment in half of the participants in the FORTITUDE study in 1H 2024 SAN DIEGO , June 20, 2023 /PRNewswire/ - - Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody... Read More

SAN DIEGO , June 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two oral presentations and two poster presentations at the 30th Annual FSHD Society International Research Congress, being held June 15-16, 2023 , in Milan,... Read More

SAN DIEGO , May 22, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,900 shares of its common... Read More

Avidity plans to double the number of participants receiving 4 mg/kg of AOC 1001 in MARINA Open-Label Extension (MARINA-OLE™) study by dose escalating participants currently on 2 mg/kg of AOC 1001 FDA allows new participant enrollment for 2 mg/kg of AOC 1001 First look at data from the MARINA-OLE study planned for the end of 2023 SAN DIEGO , May 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a... Read More

Positive topline data from AOC 1001 Phase 1/2 MARINA™ trial demonstrated functional improvement, disease modification and favorable safety and tolerability profile in people living with myotonic dystrophy type 1 Advancing three programs in clinical trials with data expected later this year - first look at data from open-label extension study, MARINA-OLE™; healthy volunteer data from EXPLORE44™ Expands research and... Read More

Topline data presented at AAN annual meeting showed AOC 1001 achieved directional improvements in multiple functional endpoint assessments - myotonia (vHOT), measures of strength (total QMT) and mobility (10mWRT, Timed Up and Go) AOC 1001 data demonstrate favorable safety/tolerability profile with most adverse events mild or moderate Topline AOC 1001 data identify dose range for pivotal study; Avidity continues to work to... Read More

SAN DIEGO , April 24, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon... Read More

SAN DIEGO , April 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 58,300 shares of its common... Read More

SAN DIEGO , April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced presentations at the 75 th American Academy of Neurology (AAN) Annual Meeting, including an oral presentation on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2... Read More

Nicholas E. Johnson , M.D., M.Sci., FAAN, MARINA lead investigator will present AOC 1001 topline data Volume 7 of investor and analyst series will be an in-person event in Boston and available via webcast SAN DIEGO , April 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™),... Read More

Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to... Read More

SAN DIEGO , March 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) , today announced that on March 20 , 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,700 shares of its... Read More

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that the company will be presenting two oral presentations and multiple poster presentations at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas , being held March 19-22, 2023... Read More

SAN DIEGO , March 1, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following conference: Cowen 43 rd Annual Healthcare Conference on March 7 at 8:10 a.m. PT/ 11:10 a.m. ET A live webcast of the event,... Read More

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate progress. "In 2022, we executed on our goal of advancing three rare disease programs... Read More

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers. "This Rare Disease Day,... Read More

Avidity adds new research and development programs in skeletal muscle and cardiology Avidity executing on three distinct rare disease programs in Phase 1/2 clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD) SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to... Read More

W. Michael Flanagan , Ph.D. named chief scientific and technical officer SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin , Ph.D. has been appointed to the board of directors of the company and is transitioning from chief... Read More

SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2023 , the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 27,400 shares of its common stock... Read More

SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a serious, rare,... Read More

SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following conference: SVB Securities Global Biopharma Conference on February 14 at 1:20 p.m. PT/ 4:20 p.m. ET A live webcast of the event,... Read More

SAN DIEGO , Jan. 20, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2023, the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and... Read More

SAN DIEGO , Jan. 18, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a serious, rare,... Read More

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share. All of the shares to be sold in the offering are to be sold... Read More

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant... Read More

AOC 1001 delivered siRNA to skeletal muscle and produced meaningful DMPK reduction in 100% of participants with a 45% mean reduction in DMPK after a single dose of 1 mg/kg or two doses of 2 mg/kg AOC 1001 produced splicing improvement of 31% in a key set of muscle-specific genes in people with DM1, with a splicing improvement of 16% across a broad 22-gene panel Early signs of clinical activity, with improvement in myotonia... Read More